CorMedix Presents New Data on Fungus Illness Test

CorMedix (NYSEMKT:CRMD) released results from a test of taurolidine, an anti-infective component of Neutrolin, against a fungus illness called Candida auris.

As quoted in the press release:
The sensitivity testing, performed by premier microbiology and antimicrobial surveillance laboratory JMI Laboratories, demonstrated that C. auris isolates were inhibited 100% at the concentration of taurolidine currently contained in Neutrolin.
Multidrug-resistant C. auris is an emerging fungus causing serious illness in humans that the CDC has cited as a “serious global health threat.” C. auris is associated with life-threatening bloodstream and wound infections, causing recent hospital outbreaks globally with high mortality. It is also able to form biofilms that enhance its pathogenicity and persistence in the hospital setting.¹
Antony E. Pfaffle, M.D. Chief Scientific Officer and Co-Founder of CorMedix, stated, “Patients at the highest risk of C. auris infection include those with central venous catheters, have undergone recent surgery, have diabetes, and have used broad-spectrum antibiotics and antifungals.²C. auris often does not respond to commonly used antifungal drugs, making infections difficult to treat. For this reason, we are pleased to see that taurolidine appears to completely inhibit this deadly pathogen in laboratory studies. The broad spectrum activity underscores the potential utility of taurolidine for development not only as the active ingredient in Neutrolin but also were it to be incorporated into sutures, hydrogels and surgical meshes in indications such as wound closure, burns, and diabetic foot ulcer. We look forward to determining a plan to work with global regulatory agencies to leverage the benefits of taurolidine to help prevent resistant microbial infections.”

Click here to read the full press release.

Source: www.accesswire.com